Education
About Us
Working with TipRanks
Follow Us
Passage Bio (PASG)
NASDAQ:PASG
PASG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.26 - $1.33
Previous CloseN/A
Volume182.24K
Average Volume (3M)345.16K
Market Cap
$23.63M
Enterprise Value$857.85M
Total Cash (Recent Filing)$63.36M
Total Debt (Recent Filing)$25.12M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Jul 31, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding62,148,273
10 Day Avg. Volume391,203
30 Day Avg. Volume345,162
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)5.83
Price to Sales (P/S)0.00
P/FCF Ratio-24.45
Enterprise Value/Market Cap36.31
Enterprise Value/Revenue72.55
Enterprise Value/Gross Profit-1.07K
Enterprise Value/Ebitda-3.30
Forecast
1Y Price Target
$6.00Price Target Upside1363.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Passage Bio News
PremiumCompany Announcements
Passage Bio Releases Promising Interim Data for PBFT02
PremiumCompany Announcements
Passage Bio Releases Promising Interim Data for PBFT02
PremiumCompany Announcements
Passage Bio Adopts Key Proposals at Annual Meeting
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEarly efficacy results from the upliFT-D study in FTD-GRN patients are encouraging, with Patient 8 showing increased CSF progranulin levels that approach the upper healthy adult range.
Financial StabilityPassage Bio announced a transition to an outsourced analytical testing model and a restructuring of headcount to reduce operating expenses, extending their cash runway into Q1:27.
Regulatory ApprovalBoth the Independent Data Monitoring Committee (IDMC) and the FDA have already agreed that the next patient can be dosed as planned, with additional safety monitoring in place.
Bears Say
Adverse EventsA new serious adverse event, pulmonary embolism, was reported in Patient 8 after treatment, prompting an amendment to the study protocol to include prophylactic anticoagulation.
Clinical Trial ChallengesThe company plans to amend the study protocol and modify inclusion criteria to study patients earlier in their disease progression, which could potentially improve safety outcomes.
Market ReactionPASG shares showed negative reaction to the clinical update from the Ph1/2 study of PBFT02 in frontotemporal dementia (FTD).
Ownership Overview
26.55% Insiders
4.94% Mutual Funds
<0.01% Other Institutional Investors
65.10% Public Companies and Individual Investors
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $0.26 and its highest was $1.33 in the past 12 months.
What is Passage Bio’s market cap?
Passage Bio’s market cap is $23.63M.
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is Jul 31, 2025 which is in 27 days.
How were Passage Bio’s earnings last quarter?
Passage Bio released its earnings results on May 13, 2025. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.23 by -$0.02.
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Undervalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate is -0.2.
How many shares outstanding does Passage Bio have?
Passage Bio has 62,148,273 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Passage Bio reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.23. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Passage Bio?
Currently, no hedge funds are holding shares in PASG
Passage Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (1363.41% Upside)
$6.00 (1363.41% Upside)
Blogger Sentiment
Bullish
PASG Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $325.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 35.0%
Last 30 Days ▲ 67.1%
Last 30 Days ▲ 67.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.35%
12-Months-Change
Fundamentals
Return on Equity
-83.73%
Trailing 12-Months
Asset Growth
-38.80%
Trailing 12-Months
Company Description
Passage Bio
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
PASG Stock 12 Month Forecast
Average Price Target
$6.00
▲(1363.41%Upside)
Technical Analysis
Tempest Therapeutics
―
Chemomab Therapeutics
―
Annovis Bio
―
Generation Bio
―
Cognition Therapeutics
―